genomic analysis of meningococcal serogroup w
DESCRIPTION
Genomic Analysis of Meningococcal Serogroup W. Xin Wang, Ph.D Meningitis Laboratory CDC. Introduction. N. meningitidis. Human commensal bacterium and also one of the common pathogens causing bacterial meningitis. - PowerPoint PPT PresentationTRANSCRIPT
1
Genomic Analysis of Meningococcal Serogroup
WXin Wang, Ph.D
Meningitis LaboratoryCDC
2
Introduction
3
Human commensal bacterium and also one of the common pathogens causing bacterial meningitis.
12 serogroups based on the structure and chemical composition of cell surface associated capsular polysaccharide.
Only six serogroups (A, B, C, W, X, and Y) are associated with most invasive disease.
N. meningitidis
4
Frequent horizontal gene transfer events and vaccine-induced immune selection
Antigenically and genetically diverse Dynamic population structure Common typing methods to determine
genetic/antigentic variations Multilocus sequence typing (MLST) Typing of outer membrane protein (OMP) encoding genes (porA,
fetA, fHbp, nadA, and nhbA) Pulse-Field Gel Electrophoresis (PFGE)
N. meningitidis
5
MLST Targets the internal region (400-
500 bps) of the 7 house-keeping genes/loci
For each locus, an allele number is assigned to each unique nucleotide sequence.
A sequence type (ST) is defined by the allelic profile of the seven loci.
Strains that have at least four alleles in common are usually defined as the same clonal complex (CC).
Maiden, M., et al. 1998. PNAS
abcZ adk aroE fumC gdh pdhC pgm ST CC4 10 5 4 6 3 8 32 CC32/ET-5 complex
6
OMP typingPorA (for porin A)• Class 1 transmembrane protein with 8 loops • Major component of OMV-based vaccines • Two hypervariable regions, VR1 (loop 1) and VR2 (loop 4).• Nomenclature: P1.5-2,16-2• VR1 & VR2 are targeted by the bactericidal antibodies and
are thus under selective pressure.FetA (ferric enterobactin transport)• Formerly FrpB (iron-repressed protein B) • 13 surface-exposed loops• One variable region: F3-3
B vaccine immunogens • FHbp, NadA and NhbA
7
Sero-group
Clonal Complex
PorA:FetA
2000-05 2006-10 p value
No. of isolates
Proportion1
No. of isolates
Proportion1
B n=298 n=127 CC41/44 P1.7-2,4:F1-5 17 5.8 2 1.4 0.02 CC32 P1.7,16-2:F3-3 9 3.1 0 0.0 0.02 P1.7,16:F3-3 49 16.6 16 12.7 0.055 C n=277 n=162 CC103 P1.5-1,10-4:F3-9 17 6.1 28 17.3 0.0002 CC11 P1.22-1,14:F3-6 23 8.3 3 1.9 0.009
P1.5,2:F1-30 32 11.6 1 0.6 <0.0001 P1.5,2:F3-6 57 20.6 18 11.1 0.03 P1.5,2:F4-12 3 1.1 28 17.3 <0.0001 P1.5-1,10-4:F3-6 25 9.0 2 1.2 0.002 P1.5-1,10-62:F3-6 0 0 21 13.0 <0.0001 Y n=319 n=196 CC23 P1.5-1,2-2:F5-8 97 30.4 95 48.5 <0.0001 P1.5-2,10-1:F4-1 167 52.4 63 32.1 0.004 NG n=29 n=19 CC32 P1.7,16:F3-3 8.0 27.6 0 0.0 0.03
Strain genotypes with significant changes between 2000-05 and 2006-10,
ABCs
(Wang et al unpublished)
8
Significant public health concern due to its high mortality rate world-wide.
Meningococcal meningitis epidemics were reported in many other countries in North America, Asia, Europe and South America.
Shift in the global epidemiology of meningococcal disease in post-vaccine era
Meningococcal disease
9
Meningitis epidemics in the meningitis belt
highest incidence (up to 1000 per 100, 000 population) found in the belt
occur in cycles of 8-10 years predominately caused by serogroup A pre-MenAfriVac
http://wwwnc.cdc.gov/travel/yellowbook/2012/
Eradication of serogroup A meningitis epidemics
MenAfriVac, an affordable serogroup A conjugate vaccine developed for African countries
Introduction in Burkina Faso, Mali and Niger in 2010 No serogroup A detected among vaccinated population
http://www.thegatesnotes.com/Topics/Health/The-MenAfriVac-Vaccine-an-Amazing-Success-Story-in-Global-Healthhttp://www.meningitis.org/assets/x/53978
11
Post-MenAfriVac Followed the implementation of MenAfriVac,
serogroup W becomes the most prevalent strain causing meningococcal disease in vaccinated countries.
There is an increase in serogroup W disease in the vaccinated countries such as Burkina Faso and Mali.
This is extremely concerning because serogroup W strains currently circulating in Africa may have the potential to cause epidemics and large outbreaks.
12
NmW and outbreaks
13
The first large NmW outbreak occurred during the Hajj pilgrimage in Saudi Arabia in 2000
More than 300 cases were reported Caused by a strain of CC11 with a PorA type of P1.5,2,
PFGE pattern 40, and 16S type 31 This strain is known as the Hajj clone
Hajj outbreak
14
Intercontinental spread of serogroup W (the Hajj clone) since Hajj outbreak: European, Asian, Middle East, North African countries and the United States.
A large outbreak involving nine European countries (the UK, France, the Netherlands, Germany, Finland, Sweden, Belgium, Switzerland, and Norway) was reported immediately following the Hajj outbreak in 2000.
A phylogenetic analysis indicated the Hajj outbreak and associated strains collected from Saudi Arabia, France, Singapore, Finland and the United States in 2000 had identical PFGE pattern (40), 16S type (31) and PorA type (P1.5,2), and belonged to the CC11 (ST-11)/ET-37 complex (ET-27).
Hajj associated outbreak
15
NmW strains from 1970-2000 that were not epidemiologically linked to the Hajj outbreak• Diverse genetic background • Some strains were genetically identical to the Hajj clone by PFGE,
MLEE and PorA typing; 16S type differs by 3 nucleotides
The Hajj-related clone circulating in different regions before 2000;
Due to the recombining nature of N. meningitidis, genetic variation occurred during the transmission
The Hajj outbreak led to the global transmission of this clone.
16
NmW in the US
No. of Isolat
es
Clonal Complex
Total CC22 CC11 CC23 CC174 CC167 CC168 unassigned95 57 5 7 3 1 1 21
(Wang et al unpublished)
Accounts for <5% of invasive meningococcal disease in the United States
14 W cases in South FL, 2008-9 (6 cases during 2004-7)CC11/ST11, and similar to the Hajj clone by PFGE
17
CC11/ET-37 complex has been present in Africa since at least 1993
In 2002, a serogroup W epidemic was reported in Burkina Faso, which affected 12,000 people and caused 1400 deaths.
Caused by a CC11 strain, showing similarity to the Hajj clone
This clonal complex continues to spread in African countries after the 2002 Burkina Faso epidemic and remains to be the prevalent genotype.
Clonal complex 175 emerged between 2002 and 2010.
NmW in Africa
18
Clonal Complex No. (%) isolates
CC11 66
CC23 1
CC175 38
NmW strains in the meningitis belt between 2004 and 2010, Pre-MenAfriVac
Caugant DA, Kristiansen PA, Wang X, Mayer LW, et al. (2012) PLoS ONE 7(9): e46019.doi:10.1371/journal.pone.0046019
19
Project Objectives
20
To determine the genetic similarity and difference of NmW strains from different geographic locations, and the genetic relatedness of these strains to the Hajj clone
To identify genetic markers associated with epidemics and outbreaks.
To determine whether capsule switching has occurred between serogroups W and C.
21
Lab_Id Year Country submission type SG ST CCM22702 1998 Algeria endemic W 8814 M23413 2011 Burkina Faso endemic W 11 CC11/ET-37M22803 2005 Chad endemic W 11 CC11/ET-37 M25087 2012 Mali endemic W 11 CC11/ET-37M07293 2000? South Africa endemic W M23347 2011 United States FL outbreak W M09261 2002 Burkina Faso epidemic W 11 CC11/ET-37 M09293 2002 Burkina Faso epidemic W M24695 2010 Burkina Faso epidemic X 181 CC181M22811 2006 Niger epidemic W 2881 CC175
M22831 2009 Niger epidemic A 2859CC5/subgroup
IIIM07149 2000 Saudi Arabia epidemic W 11 CC11/ET-37 M22822 2007 Togo epidemic W 2881 CC175M25419 2005 South Africa source unknown W M22819 2007 Benin sporadic W 2881 CC175M22740 2001 Cameroon sporadic W 11 CC11/ET-37
M22748 2001Central African
Republic sporadic W 11 CC11/ET-37M22801 2004 Djibouti sporadic W 11 CC11/ET-37 M22471 1993 France sporadic W 22 CC22M22751 2002 France sporadic W 11 CC11/ET-37 M07165 1995 Gambia sporadic W 11 CC11/ET-37 M22189 2007 Mali sporadic W 11 CC11/ET-37M22718 2001 Mauritius sporadic W 11 CC11/ET-37 M22772 2002 Senegal sporadic W 11 CC11/ET-37 M25543 2012 United States sporadic W
PorA, FetA, 16S, FHbp, NadA, NhbA etc?
22
Meningitis Belt Country
Non-Belt African Country
Others
Burkina Faso Algeria FranceBenin Djibouti United State
Cameroon Mauritius Saudi ArabiaChad South Africa
Central African of RepublicGambia
MaliNiger
SenegalTogo
Strain collection
23
24
Strain collection
Submission type Epidemic vs Endemic
Outbreak vs sporadic Serogroup
W A X
25
Strain collectionLab ID Year CountryM09261 2002 Burkina FasoM09293 2002 Burkina FasoM24695 2010 Burkina FasoM23413 2011 Burkina FasoM22471 1993 FranceM22751 2002 FranceM22189 2007 MaliM25087 2012 MaliM22811 2006 NigerM22831 2009 NigerM07293 2000? South AfricaM25419 2005 South AfricaM23347 2011 United StatesM25543 2012 United States
26unpublished
Nov 18-28, 2013
Nov 12-14, 2013
March 6, 2013
27
Capsular Switching
Allelic exchange of serogroup-specific gene(Swartley et al 1997)
A capsule switching event is defined as an isolate of a certain serogroup belonging to a clonal complex that is commonly associated with a different serogroup.
A possible mechanism to escape the host immune system
28
The cap locus of N. meningitidis
B cssA cssB cssCctrBctrD ctrAtex ctrC galEcsb
A csaA csaB csaCctrBctrD ctrAtex ctrC csaD galE
C cssA cssBctrBctrD ctrAtex ctrC cssC csc galE
Y cssB cssC csyctrBctrD ctrAtex ctrC cssA galE
W cssA cssB cssC cswctrBctrD ctrAtex ctrC galE
NG tex galE…other genetic mutations possible
X ctrBctrD ctrAtex ctrC csxA csxB csxC galE
Capsule TransportGenogroup-specific Capsule BiosynthesisGenogroup
29
Capsular switching events among the US isolates from 2006-10, ABCs
Serogroup B to C (n=56) Switching from C to B (n=10) Switching between Y and W in both directions
(n=10). Switching from B/C to Y/W (n=4) and Y/W to B/C
(n=7) Switching from B, C, Y and W to other
serogroups (n=9)
30
CC11/ET-37 complex is usually associated with serogroup C.
Capsule switching might have occurred between serogroups W and C, but when and in which direction is not known
Capsular Switching between C and W
31
Acknowledgement
CDC MVPDB Meningitis Laboratory
CDC MVPDB epidemiology team
National Reference Laboratories (CHUP-CDG, CHU-YO, CHU-SS, and CM, Burkina Faso)
National Reference Laboratory, Mali
Dr. Pierre Nicolas, former WHO CC, France